Coherus Oncology paid its 3 named executives $5.1M in total in FY2025 (Dec). CEO Dennis M. Lanfear was paid $2.7M of that.
Pay$100 in the stock at the end of FY20 → $8
Pay of each named executive
Dennis M. LanfearPresident, Chief Executive Officer and Chairman of the Board of Directors
| FY2025 (Dec) | Not disclosed | ||||||
| FY2024 (Dec) | Not disclosed | ||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
Paul ReiderFormer Chief Commercial Officer
| FY2025 (Dec) | Not disclosed | ||||||
| FY2024 (Dec) | Not disclosed | ||||||
| FY2023 (Dec) |
3 years
Bryan McMichaelChief Financial Officer
| FY2025 (Dec) | Not disclosed | ||||||
| FY2024 (Dec) | Not disclosed | ||||||
| FY2023 (Dec) |
3 years
CEO pay against the pay peers
In FY2023 (Dec), the median CEO pay of the 7 peers with pay on file was $6.5M. The CEO of Coherus Oncology was paid $5.9M, 9% below the median.
- 1PTC Therapeutics
- 2Ironwood Pharmaceuticals
- 3Pacira BioSciences
- 4Mirum Pharmaceuticals
- 5Coherus OncologyThis company
- 6Agenus
- 7Agios Pharmaceuticals
- 8Nektar Therapeutics
- 9Acadia PharmaceuticalsNot disclosed
- 10Aerie PharmaceuticalsNot disclosed
- 11Amicus PharmaceuticalsNot disclosed
- 12Collegium PharmaceuticalsNot disclosed
- 13Corcept TherapeuticsNot disclosed
- 14Deciphera PharmaceuticalsNot disclosed
- 15Dynavax TechnologiesNot disclosed
- 16Eagle PharmaceuticalsNot disclosed
- 17FibrogenNot disclosed
- 18Heron TherapeuticsNot disclosed
- 19Intercept PharmaceuticalsNot disclosed
- 20Karyopharm TherapeuticsNot disclosed
- 21Supemus PharmaceuticalsNot disclosed
- 22Vanda PharmaceuticalsNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.